Abstract
BackgroundDiscontinuation of biologics without flaring in RA patients is our next treatment goal, which contributes to reduce economic burden and safety risk such as infections. There are some reports of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
